Kersting, D., Kim, M., Puellen, L., Seidl-Rathkopf, K., Schinwald, N., Mpofu, P., . . . Hadaschik, B. A. (2024). Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting. Journal of Clinical Oncology, 42, 143. https://doi.org/10.1200/JCO.2024.42.4_suppl.143
Παραπομπή σε μορφή Chicago (17η εκδ.)Kersting, David, et al. "Characteristics and Outcomes of Patients (pts) with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Lutetium-177–PSMA-617 (PSMA-RLT) in a Real-world Setting." Journal of Clinical Oncology 42 (2024): 143. https://doi.org/10.1200/JCO.2024.42.4_suppl.143.
Παραπομπή σε μορφή MLA (9th εκδ.)Kersting, David, et al. "Characteristics and Outcomes of Patients (pts) with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Lutetium-177–PSMA-617 (PSMA-RLT) in a Real-world Setting." Journal of Clinical Oncology, vol. 42, 2024, p. 143, https://doi.org/10.1200/JCO.2024.42.4_suppl.143.